Jazz Pharma Plc (JAZZ)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
| 12-2020 | 12-2019 | 12-2018 | 12-2017 | 12-2016 | |
| Cash Flows From Operating Activities | |||||
| Net Income | 238,616 | 523,367 | 447,098 | 487,848 | 396,831 |
| Depreciation Amortization | 278,253 | 370,156 | 260,691 | 195,180 | 135,913 |
| Income taxes - deferred | -136,937 | -236,610 | -88,815 | -225,591 | -41,163 |
| Accounts receivable | -38,647 | -92,326 | -40,132 | 12,278 | -25,603 |
| Accounts payable and accrued liabilities | -18,935 | 4,770 | 17,040 | 214 | 361 |
| Other Working Capital | -85,437 | -154,173 | 21,083 | 26,766 | -20,864 |
| Other Operating Activity | 662,735 | 361,217 | 181,939 | 196,392 | 146,916 |
| Operating Cash Flow | $899,648 | $776,401 | $798,904 | $693,087 | $592,391 |
| Cash Flows From Investing Activities | |||||
| Change In Deposits | -642,675 | 67,900 | -310,915 | -155,000 | -65,275 |
| PPE Investments | -15,004 | -25,926 | 27,528 | -28,950 | -9,687 |
| Net Acquisitions | 14,259 | -55,074 | N/A | N/A | -1,502,443 |
| Purchase Sale Intangibles | -364,250 | -142,200 | -111,100 | -85,000 | -173,750 |
| Other Investing Activity | -364,250 | -142,200 | -111,100 | -85,000 | -173,750 |
| Investing Cash Flow | $-1,007,670 | $-155,300 | $-394,487 | $-268,950 | $-1,751,155 |
| Cash Flows From Financing Activities | |||||
| Debt Issued | 1,481,381 | 0 | 0 | 559,393 | 994,647 |
| Debt Repayment | -889,575 | -33,387 | -25,717 | -886,094 | -178,304 |
| Common Stock Issued | 99,681 | 57,831 | 93,337 | 31,824 | 24,174 |
| Common Stock Repurchased | -146,537 | -301,450 | -523,672 | -98,799 | -278,296 |
| Other Financing Activity | -16,877 | -16,739 | -23,078 | -15,435 | -21,234 |
| Financing Cash Flow | $528,073 | $-293,745 | $-479,130 | $-409,111 | $540,987 |
| Exchange Rate Effect | 374 | 366 | -1,700 | 5,046 | -5,045 |
| Beginning Cash Position | 637,344 | 309,622 | 386,035 | 365,963 | 988,785 |
| End Cash Position | 1,057,769 | 637,344 | 309,622 | 386,035 | 365,963 |
| Net Cash Flow | $420,425 | $327,722 | $-76,413 | $20,072 | $-622,822 |
| Free Cash Flow | |||||
| Operating Cash Flow | 899,648 | 776,401 | 798,904 | 693,087 | 592,391 |
| Capital Expenditure | -15,004 | -40,135 | -20,370 | -28,950 | -9,687 |
| Free Cash Flow | 884,644 | 736,266 | 778,534 | 664,137 | 582,704 |